This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kavelaars, A. Articles by Heijnen, C. J. Search for Related Content PubMed PubMed Citation Articles by Kavelaars, A. Articles by Heijnen, C. J.

Disturbed Neuroendocrine-Immune Interactions in Chronic Fatigue Syndrome¹

Departments of Pediatric Immunology (A.K., W.K., L.K., C.J.H.) and Psychology (G.S.), Wilhelmina Children’s Hospital of the University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands

Address correspondence and requests for reprints to: Dr. Annemieke Kavelaars, Wilhelmina Children’s Hospital of the University Medical Center Utrecht, Department of Pediatric Immunology, Room KC 03.068.0, Lundlaan 6, 3584 EA Utrecht, The Netherlands. E-mail: a.kavelaars{at}wkz.azu.nl

The present study was designed to investigate the interaction between neuroendocrine mediators and the immune system in chronic fatigue syndrome (CFS). We examined the sensitivity of the immune system to the glucocorticoid agonist dexamethasone and the ß2-adrenergic agonist terbutaline in 15 adolescent girls with CFS and 14 age- and sex-matched controls. Dexamethasone inhibits T-cell proliferation in healthy controls and in CFS patients. However, the maximal effect of dexamethasone on T-cell proliferation is significantly reduced in CFS patients as compared with controls. The ß2-adrenergic receptor agonist terbutaline inhibits tumor necrosis factor- production and enhances interleukin-10 production by monocytes. Our data demonstrate that the capacity of a ß2-adrenergic agonist to regulate the production of these two cytokines is also reduced in CFS patients. We did not observe differences in baseline or CRH-induced cortisol and ACTH between CFS patients and controls. Baseline noradrenaline was similar in CFS and controls, whereas baseline adrenaline levels were significantly higher in CFS patients.

We conclude that CFS is accompanied by a relative resistance of the immune system to regulation by the neuroendocrine system. Based on these data, we suggest CFS should be viewed as a disease of deficient neuroendocrine-immune communication.

This article has been cited by other articles:

				B. Van Houdenhove, L. Verheyen, K. Pardaens, P. Luyten, and P. Van Wambeke Rehabilitation of decreased motor performance in patients with chronic fatigue syndrome: should we treat low effort capacity or reduced effort tolerance? Clinical Rehabilitation, December 1, 2007; 21(12): 1121 - 1142. [Abstract] [PDF]

				V. B. Wyller, K. Godang, L. Morkrid, J. P. Saul, E. Thaulow, and L. Walloe Abnormal Thermoregulatory Responses in Adolescents With Chronic Fatigue Syndrome: Relation to Clinical Symptoms Pediatrics, July 1, 2007; 120(1): e129 - e137. [Abstract] [Full Text] [PDF]

				P. M. C. Mommersteeg, C. J. Heijnen, A. Kavelaars, and L. J. P. van Doornen Immune and Endocrine Function in Burnout Syndrome Psychosom Med, November 1, 2006; 68(6): 879 - 886. [Abstract] [Full Text] [PDF]

				A. Di Giorgio, M. Hudson, W. Jerjes, and A. J. Cleare 24-Hour Pituitary and Adrenal Hormone Profiles in Chronic Fatigue Syndrome Psychosom Med, May 1, 2005; 67(3): 433 - 440. [Abstract] [Full Text] [PDF]

				D. Ait-Ali, V. Turquier, L. Grumolato, L. Yon, M. Jourdain, D. Alexandre, L. E. Eiden, H. Vaudry, and Y. Anouar The Proinflammatory Cytokines Tumor Necrosis Factor-{alpha} and Interleukin-1 Stimulate Neuropeptide Gene Transcription and Secretion in Adrenochromaffin Cells via Activation of Extracellularly Regulated Kinase 1/2 and p38 Protein Kinases, and Activator Protein-1 Transcription Factors Mol. Endocrinol., July 1, 2004; 18(7): 1721 - 1739. [Abstract] [Full Text] [PDF]

				A. J. Cleare The Neuroendocrinology of Chronic Fatigue Syndrome Endocr. Rev., April 1, 2003; 24(2): 236 - 252. [Abstract] [Full Text] [PDF]

				H. Vermeer, B. I. Hendriks-Stegeman, B. van der Burg, S. C. van Buul-Offers, and M. Jansen Glucocorticoid-Induced Increase in Lymphocytic FKBP51 Messenger Ribonucleic Acid Expression: A Potential Marker for Glucocorticoid Sensitivity, Potency, and Bioavailability J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 277 - 284. [Abstract] [Full Text] [PDF]

				B. H. Natelson, M. H. Haghighi, and N. M. Ponzio Evidence for the Presence of Immune Dysfunction in Chronic Fatigue Syndrome Clin. Vaccine Immunol., July 1, 2002; 9(4): 747 - 752. [Full Text] [PDF]

				J. E. Bower, P. A. Ganz, N. Aziz, and J. L. Fahey Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors Psychosom Med, July 1, 2002; 64(4): 604 - 611. [Abstract] [Full Text] [PDF]

				L. Knook, A. Kavelaars, G. Sinnema, W. Kuis, and C. J. Heijnen High Nocturnal Melatonin in Adolescents with Chronic Fatigue Syndrome J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3690 - 3692. [Abstract] [Full Text]